קמפטו - Campto
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01XX Other antineoplastic agents | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | ||||||||||||||||||||||||||||||
| צ×רת ××× ×× | ת×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||||||||
| ×ת×××× | Campto is indicated for the treatment of patients with metastatic colorectal cancer: In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. For the treatment of patients with small cell lung cancer. For the treatment of patients with gastric cancer.Irinotecan in combination with leucovorin, Oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ק×פ×× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | PFIZER (PERTH) PTY LIMITED, AUSTRALIA |
| ×©× ××¢× ×ר×ש×× | PFIZER PFE PHARMACEUTICALS ISRAEL LTD |
| ר×ש××× | ת×ר×× ××ש×: 12/1996. ר×ש××× ×ת×ר××: 12/2011 |
| ת×ר×× ×¢×××× ××ר×× | 14/05/19 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־16 במרץ 2014 ב־20:49